NCT06665997View on ClinicalTrials.gov

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Sickle Cell Disease (SCD)Vaso-Occlusive Pain Episode in Sickle Cell Disease
Interventions
DRUG

Depot medroxyprogesterone acetate (DMPA)

150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension

Trial Locations (2)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

30322

NOT_YET_RECRUITING

Emory University, Atlanta

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Emory University

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

lead

University of Pennsylvania

OTHER